BRPI0917147B8 - composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto - Google Patents

composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto

Info

Publication number
BRPI0917147B8
BRPI0917147B8 BRPI0917147A BRPI0917147A BRPI0917147B8 BR PI0917147 B8 BRPI0917147 B8 BR PI0917147B8 BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 B8 BRPI0917147 B8 BR PI0917147B8
Authority
BR
Brazil
Prior art keywords
compound
salt
making
compounds
alzheimer
Prior art date
Application number
BRPI0917147A
Other languages
English (en)
Inventor
Swahn Britt-Marie
Ruda Katinka
Anders Nilsson Nils
Magnus Schou Per
JOHNSTRÖM Peter
Björk Seth
Delisser Vern
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0917147A2 publication Critical patent/BRPI0917147A2/pt
Publication of BRPI0917147B1 publication Critical patent/BRPI0917147B1/pt
Publication of BRPI0917147B8 publication Critical patent/BRPI0917147B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

composto ou sal deste uso de um composto ou sal deste, e, processo para fabricar um composto. a presente invenção diz respeito a novos derivados que são adequados como percursores para compostos que são úteis para formação de imagem de depósitos de amilóide em pacientes vivos, as suas composições métodos de uso e processos para fabricar tais componentes. os compostos que derivam destes precursores dão úteis nos métodos de formação de imagem de depósitos de amilóide no cérebro in vivo para permitir diagnóstico anterior á morte da doença de alzheimer pela tomografia de emissão de pósitron (pet) assi, como medir a eficácia clínica de agentes terapêuticos para a doença de alzheimer. além disso, a presente invenção também divulga os compostos precursores na forma cristalina.
BRPI0917147A 2008-08-29 2009-08-28 composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto BRPI0917147B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9285108P 2008-08-29 2008-08-29
US61/092851 2008-08-29
PCT/SE2009/050972 WO2010024769A1 (en) 2008-08-29 2009-08-28 New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits

Publications (3)

Publication Number Publication Date
BRPI0917147A2 BRPI0917147A2 (pt) 2015-11-17
BRPI0917147B1 BRPI0917147B1 (pt) 2020-09-15
BRPI0917147B8 true BRPI0917147B8 (pt) 2021-05-25

Family

ID=41721733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917147A BRPI0917147B8 (pt) 2008-08-29 2009-08-28 composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto

Country Status (22)

Country Link
US (3) US8193363B2 (pt)
EP (1) EP2328891B1 (pt)
JP (1) JP5613669B2 (pt)
KR (1) KR101648848B1 (pt)
CN (3) CN104478862B (pt)
AR (2) AR073230A1 (pt)
AU (1) AU2009286176B2 (pt)
BR (1) BRPI0917147B8 (pt)
CA (1) CA2735497C (pt)
CL (1) CL2011000420A1 (pt)
CO (1) CO6341628A2 (pt)
EA (1) EA019093B1 (pt)
EC (1) ECSP11010850A (pt)
ES (1) ES2627769T3 (pt)
IL (1) IL211188A0 (pt)
MX (1) MX2011001918A (pt)
NZ (1) NZ591446A (pt)
PE (1) PE20110393A1 (pt)
TW (1) TW201014848A (pt)
UY (1) UY32076A (pt)
WO (1) WO2010024769A1 (pt)
ZA (1) ZA201102284B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
KR102053484B1 (ko) 2012-12-21 2019-12-06 국립연구개발법인 양자과학기술연구개발기구 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
KR20180113975A (ko) * 2015-11-20 2018-10-17 나비디아 바이오파마슈티컬즈, 인크. 2-헤테로아릴 치환된 벤조푸란에 대한 제제
JP2023502605A (ja) 2019-11-13 2023-01-25 アプリノイア セラピューティクス リミテッド タウタンパク質凝集物を分解する化合物及びその使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041525A (en) 1964-11-11 1966-09-07 Belge Produits Chimiques Sa Benzofuran derivatives and processes for preparing the same
CA2176127A1 (en) 1993-12-21 1995-06-29 William Henry Walker Lunn Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
DE60009116T2 (de) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
FR2800069A1 (fr) * 1999-10-22 2001-04-27 Centre Nat Rech Scient 3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
JP4307001B2 (ja) 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
DE60326735D1 (de) 2002-08-02 2009-04-30 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
EP1631561B1 (en) * 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
CA2530389A1 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
US7541357B2 (en) * 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2457901A1 (en) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
JP5121707B2 (ja) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー 新規医薬
WO2007047204A1 (en) * 2005-10-11 2007-04-26 University Of Pittsburgh Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2113258A1 (en) * 2006-12-05 2009-11-04 Nagasaki University Aurone derivative-containing composition for diagnosis
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Also Published As

Publication number Publication date
US20100056796A1 (en) 2010-03-04
JP5613669B2 (ja) 2014-10-29
NZ591446A (en) 2012-08-31
US9309267B2 (en) 2016-04-12
CL2011000420A1 (es) 2011-07-15
JP2012501324A (ja) 2012-01-19
TW201014848A (en) 2010-04-16
AU2009286176A1 (en) 2010-03-04
CN102197036A (zh) 2011-09-21
AR073230A1 (es) 2010-10-20
CN104447710A (zh) 2015-03-25
US8653274B2 (en) 2014-02-18
CA2735497C (en) 2016-07-19
EA201100267A1 (ru) 2011-10-31
US8193363B2 (en) 2012-06-05
CO6341628A2 (es) 2011-11-21
BRPI0917147B1 (pt) 2020-09-15
WO2010024769A1 (en) 2010-03-04
EP2328891B1 (en) 2017-04-05
KR101648848B1 (ko) 2016-08-17
ES2627769T3 (es) 2017-07-31
MX2011001918A (es) 2011-03-24
ECSP11010850A (es) 2011-03-31
PE20110393A1 (es) 2011-07-15
US20120264943A1 (en) 2012-10-18
CN104478862B (zh) 2017-05-24
UY32076A (es) 2010-03-26
ZA201102284B (en) 2012-09-26
BRPI0917147A2 (pt) 2015-11-17
EA019093B1 (ru) 2014-01-30
KR20110045023A (ko) 2011-05-03
IL211188A0 (en) 2011-04-28
CN102197036B (zh) 2014-12-10
AR114029A2 (es) 2020-07-15
CA2735497A1 (en) 2010-03-04
CN104478862A (zh) 2015-04-01
AU2009286176B2 (en) 2012-04-26
US20140296534A1 (en) 2014-10-02
EP2328891A4 (en) 2012-07-04
EP2328891A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
BR112016028345A8 (pt) composto, composição farmacêutica, sal farmaceuticamente aceitável de um composto, e, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente
WO2009155017A3 (en) Novel substituted azabenzoxazoles
BR112014012822A8 (pt) Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0913609B8 (pt) composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
CN103906745A (zh) 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
WO2010051196A8 (en) Novel substituted azabenzoxazoles
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
MX2017003470A (es) Inhibidores macrociclicos de cinasa lrrk2.
EA202091766A1 (ru) Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
WO2010096426A8 (en) Compounds, compositions, methods of synthesis, and methods of treatment
EA201300479A1 (ru) Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы
SG194759A1 (en) Novel precursors of glutamate derivatives
NZ591824A (en) Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
TH112395A (th) สารประกอบชนิดใหม่ที่เหมาะสมเป็นพรีเคอเซอร์ไปเป็นสารประกอบที่มีประโยชน์สำหรับการถ่ายภาพการสะสมอะมัยลอยด์
TH112395B (th) สารประกอบชนิดใหม่ที่เหมาะสมเป็นพรีเคอเซอร์ไปเป็นสารประกอบที่มีประโยชน์สำหรับการถ่ายภาพการสะสมอะมัยลอยด์

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF